Cargando…

Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases

Trigeminal neuralgia is a chronic pain condition associated with sharp, shock-like pain in one or more divisions of the trigeminal nerve. For patients who do not respond well to pharmacotherapy, there is growing evidence that Botulinum toxin type A injections into the trigeminal ganglion provide pai...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearl, Craig, Moxley, Brendan, Perry, Andrew, Demian, Nagi, Dallaire-Giroux, Cyndie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689410/
https://www.ncbi.nlm.nih.gov/pubmed/36354652
http://dx.doi.org/10.3390/dj10110207
_version_ 1784836527238414336
author Pearl, Craig
Moxley, Brendan
Perry, Andrew
Demian, Nagi
Dallaire-Giroux, Cyndie
author_facet Pearl, Craig
Moxley, Brendan
Perry, Andrew
Demian, Nagi
Dallaire-Giroux, Cyndie
author_sort Pearl, Craig
collection PubMed
description Trigeminal neuralgia is a chronic pain condition associated with sharp, shock-like pain in one or more divisions of the trigeminal nerve. For patients who do not respond well to pharmacotherapy, there is growing evidence that Botulinum toxin type A injections into the trigeminal ganglion provide pain relief for several weeks up to several months at a time. One option is to administer injections into the trigeminal ganglion in Meckel’s cave by inserting a needle through the Pterygopalatine Fossa using fluoroscopy to guide and confirm the proper needle placement. However, there is evidence that Botulinum toxin travels across nerve synapses; thus, injecting directly into the trigeminal ganglion may not be necessary. We present two patients with a confirmed diagnosis of trigeminal neuralgia who were treated by injecting Botulinum toxin type A intraorally into the mental foramen which resulted in 6 months or longer of pain relief. Injections into the mental foramen are much easier to administer than those administered directly into the trigeminal ganglion, and both patients treated with this technique experienced comparable results to what can be expected from traditional fluoroscopy-guided botulinum toxin injections. Though more research is needed, these cases potentially imply that a less-invasive injection may be sufficient in managing trigeminal neuralgia-related pain.
format Online
Article
Text
id pubmed-9689410
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96894102022-11-25 Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases Pearl, Craig Moxley, Brendan Perry, Andrew Demian, Nagi Dallaire-Giroux, Cyndie Dent J (Basel) Case Report Trigeminal neuralgia is a chronic pain condition associated with sharp, shock-like pain in one or more divisions of the trigeminal nerve. For patients who do not respond well to pharmacotherapy, there is growing evidence that Botulinum toxin type A injections into the trigeminal ganglion provide pain relief for several weeks up to several months at a time. One option is to administer injections into the trigeminal ganglion in Meckel’s cave by inserting a needle through the Pterygopalatine Fossa using fluoroscopy to guide and confirm the proper needle placement. However, there is evidence that Botulinum toxin travels across nerve synapses; thus, injecting directly into the trigeminal ganglion may not be necessary. We present two patients with a confirmed diagnosis of trigeminal neuralgia who were treated by injecting Botulinum toxin type A intraorally into the mental foramen which resulted in 6 months or longer of pain relief. Injections into the mental foramen are much easier to administer than those administered directly into the trigeminal ganglion, and both patients treated with this technique experienced comparable results to what can be expected from traditional fluoroscopy-guided botulinum toxin injections. Though more research is needed, these cases potentially imply that a less-invasive injection may be sufficient in managing trigeminal neuralgia-related pain. MDPI 2022-11-03 /pmc/articles/PMC9689410/ /pubmed/36354652 http://dx.doi.org/10.3390/dj10110207 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Pearl, Craig
Moxley, Brendan
Perry, Andrew
Demian, Nagi
Dallaire-Giroux, Cyndie
Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title_full Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title_fullStr Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title_full_unstemmed Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title_short Management of Trigeminal Neuralgia with Botulinum Toxin Type A: Report of Two Cases
title_sort management of trigeminal neuralgia with botulinum toxin type a: report of two cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689410/
https://www.ncbi.nlm.nih.gov/pubmed/36354652
http://dx.doi.org/10.3390/dj10110207
work_keys_str_mv AT pearlcraig managementoftrigeminalneuralgiawithbotulinumtoxintypeareportoftwocases
AT moxleybrendan managementoftrigeminalneuralgiawithbotulinumtoxintypeareportoftwocases
AT perryandrew managementoftrigeminalneuralgiawithbotulinumtoxintypeareportoftwocases
AT demiannagi managementoftrigeminalneuralgiawithbotulinumtoxintypeareportoftwocases
AT dallairegirouxcyndie managementoftrigeminalneuralgiawithbotulinumtoxintypeareportoftwocases